OHSU researchers have identified a mechanism by which sympathetic nerves — the body's stress-response wiring — may directly fuel pancreatic cancer growth, a finding that could reshape therapeutic approaches to one of oncology's most lethal malignancies. The study demonstrates that sympathetic nerve signaling promotes tumor microenvironment changes that accelerate pancreatic ductal adenocarcinoma progression, suggesting that interventions targeting neural pathways could complement existing treatment regimens.

Pancreatic cancer carries a five-year survival rate of roughly 12% — the lowest of any major cancer — largely because it is typically diagnosed at advanced stages and responds poorly to chemotherapy. The OHSU team's work adds to a growing body of evidence that the nervous system plays an active, not passive, role in tumor biology. Beta-blockers and other sympatholytic agents, already widely prescribed for cardiovascular conditions, are now being evaluated as adjunctive cancer therapies based on findings like these. The research opens a potential repurposing pathway that could accelerate clinical translation far faster than novel drug development.

For Oregon healthcare professionals, this research reinforces OHSU's position as a nationally significant cancer research institution and has near-term clinical relevance. Oncologists should monitor emerging trials involving beta-blocker adjunct therapy for pancreatic cancer. Primary care providers managing patients with pancreatic cancer risk factors — family history, chronic pancreatitis, new-onset diabetes — should be aware that the stress-cancer connection is moving from hypothesis to mechanistic evidence. Integrative medicine practitioners may also find validation for stress-reduction interventions as part of comprehensive cancer care plans.

Watch for whether OHSU launches a clinical trial combining sympathetic nerve blockade with standard pancreatic cancer chemotherapy protocols.